[go: up one dir, main page]

CU20190105A7 - Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico y composiciones farmacéuticas de esta - Google Patents

Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico y composiciones farmacéuticas de esta

Info

Publication number
CU20190105A7
CU20190105A7 CU2019000105A CU20190105A CU20190105A7 CU 20190105 A7 CU20190105 A7 CU 20190105A7 CU 2019000105 A CU2019000105 A CU 2019000105A CU 20190105 A CU20190105 A CU 20190105A CU 20190105 A7 CU20190105 A7 CU 20190105A7
Authority
CU
Cuba
Prior art keywords
mcl
inhibitor
combination
pharmaceutical compositions
hematological cancer
Prior art date
Application number
CU2019000105A
Other languages
English (en)
Inventor
Olivier Geneste
Ana Leticia Maragno
Donia Moujalled
Giovanna Pomilio
Andrew Wei
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of CU20190105A7 publication Critical patent/CU20190105A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>Una combinación que comprende un inhibidor de Mcl-1 y un segundo agente anticanceroso, en la<br /> que el segundo agente anticanceroso se selecciona de antraciclinas, citarabina y agentes hipometilantes, y composiciones y usos de esta.</p>
CU2019000105A 2017-06-22 2018-06-21 Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico y composiciones farmacéuticas de esta CU20190105A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523389P 2017-06-22 2017-06-22
EP17189550 2017-09-06
PCT/EP2018/066551 WO2018234433A1 (en) 2017-06-22 2018-06-21 COMBINATION OF MCL-1 INHIBITOR AND CARE TREATMENT STANDARD FOR HEMATOLOGICAL CANCERS, USES AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS

Publications (1)

Publication Number Publication Date
CU20190105A7 true CU20190105A7 (es) 2020-10-20

Family

ID=62631122

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000105A CU20190105A7 (es) 2017-06-22 2018-06-21 Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico y composiciones farmacéuticas de esta

Country Status (28)

Country Link
US (1) US11466023B2 (es)
EP (1) EP3641775B1 (es)
JP (1) JP7186731B2 (es)
KR (1) KR20200018681A (es)
CN (2) CN111032050B (es)
AR (1) AR112202A1 (es)
AU (1) AU2018288520B2 (es)
BR (1) BR112019026959A2 (es)
CA (1) CA3068096C (es)
CL (1) CL2019003763A1 (es)
CO (1) CO2019014479A2 (es)
CU (1) CU20190105A7 (es)
EA (1) EA202090082A1 (es)
ES (1) ES2971466T3 (es)
GE (2) GEP20227357B (es)
IL (1) IL271475B2 (es)
JO (1) JOP20190287A1 (es)
MA (1) MA49444A (es)
MX (1) MX393811B (es)
MY (1) MY199286A (es)
NI (1) NI201900128A (es)
PH (1) PH12019502789A1 (es)
SG (1) SG11201911891WA (es)
TW (1) TWI753178B (es)
UA (1) UA126920C2 (es)
UY (1) UY37777A (es)
WO (1) WO2018234433A1 (es)
ZA (1) ZA201908446B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024520801A (ja) 2021-06-11 2024-05-24 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ
CA3222752A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002348178A1 (en) * 2002-11-06 2004-06-03 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
CA2746256C (en) * 2008-12-09 2020-03-24 Loren D. Walensky Methods and compositions for specific modulation of mcl-1
ES2602475T3 (es) * 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
CA2712747A1 (en) * 2010-08-11 2012-02-11 Universite De Montreal Combinatory cancer treatment
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR112016029041A8 (pt) * 2014-06-13 2021-07-20 Calithera Biosciences Inc uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
FR3037959B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20190062428A1 (en) * 2017-06-19 2019-02-28 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof

Also Published As

Publication number Publication date
IL271475B1 (en) 2023-05-01
MX393811B (es) 2025-03-24
JP7186731B2 (ja) 2022-12-09
CN117959451A (zh) 2024-05-03
CL2019003763A1 (es) 2020-06-19
IL271475A (en) 2020-01-30
GEAP202115242A (en) 2021-11-10
CN111032050B (zh) 2024-01-19
RU2020101626A (ru) 2021-07-22
US20200392151A1 (en) 2020-12-17
AU2018288520B2 (en) 2024-05-30
EP3641775A1 (en) 2020-04-29
MA49444A (fr) 2020-04-29
ZA201908446B (en) 2023-10-25
MY199286A (en) 2023-10-24
EA202090082A1 (ru) 2020-05-22
KR20200018681A (ko) 2020-02-19
BR112019026959A2 (pt) 2020-07-07
NI201900128A (es) 2020-03-30
US11466023B2 (en) 2022-10-11
GEP20227357B (en) 2022-02-25
CA3068096A1 (en) 2018-12-27
PH12019502789A1 (en) 2020-09-14
AR112202A1 (es) 2019-10-02
TW201904579A (zh) 2019-02-01
UA126920C2 (uk) 2023-02-22
CA3068096C (en) 2022-10-04
IL271475B2 (en) 2023-09-01
JP2020524681A (ja) 2020-08-20
CN111032050A (zh) 2020-04-17
CO2019014479A2 (es) 2020-02-28
WO2018234433A1 (en) 2018-12-27
SG11201911891WA (en) 2020-01-30
ES2971466T3 (es) 2024-06-05
UY37777A (es) 2019-01-31
RU2020101626A3 (es) 2021-10-05
EP3641775B1 (en) 2023-12-06
TWI753178B (zh) 2022-01-21
AU2018288520A1 (en) 2020-01-16
JOP20190287A1 (ar) 2019-12-16

Similar Documents

Publication Publication Date Title
SV2018005778A (es) Derivados aromaticos de sulfonamida
CL2020001312A1 (es) Composiciones de cannabidiol y usos de las mismas. (divisional solicitud 201803425).
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
ES3052961T3 (en) Cannabinoid pouch
MX378386B (es) Composiciones antiirritantes sinérgicas de taurina y aloe.
CL2011002595A1 (es) Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
UY37342A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
CO7131368A2 (es) (r)-nifuratel, su uso para el tratamiento de infecciones y síntesis de (r) y (s)-nifuratel
MX2017014235A (es) Formulaciones de emulsion estable de compuestos volatiles encapsulados.
MX393548B (es) Composiciones y usos de polipéptidos catiónicos, sintéticos, antimicrobianos localmente aplicados con seguridad y desempeño mejorados.
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
CL2019002514A1 (es) Composiciones cosméticas para el cuidado de la piel.
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
NI201900128A (es) Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico, usos y composiciones farmacéuticas de esta
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
BR112021000279A8 (pt) formulações de redução de tumor e métodos de uso das mesmas
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
BR112019000706A2 (pt) agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
ECSP19006687A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl-1, usos y composiciones farmacéuticas de éstos
CO2019007261A2 (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CU20180127A7 (es) Composiciones inmunogénicas de chagas